Meningococcal group B vaccine Disease Interactions

In patients with thrombocytopenia or coagulation disorders, IM injections may produce bleeding and hematomas. Patients with a platelet count less than 50,000/mm3 are at an increased risk. Caution is advised if the vaccine (e.g., plague vaccine; hepatitis A and B vaccines; aluminum-adsorbed DTaP, DTP, DT, or Td) must be administered IM. The risk of bleeding may be minimized by vaccination immediately after the administration of replacement factor, use of a 23-gauge (or smaller) needle, and immediate application of direct pressure to the vaccination site for at least 2 minutes.

The expected antibody responses may not be obtained when live attenuated vaccines and/or toxoids are administered to immunosuppressed persons, including those receiving immunosuppressive therapy. Caution and close monitoring is advised.